PRVA · Privia Health Group, Inc.
Market Cap
$2.64B
Shares
127.73M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$20.64
Open$20.33
Day$20.33–21.03
52W close$20.02–28.10
Avg vol 30d1.1M
Short int5.3M · 4.1% float · 3.4d
Short vol44%
Last earningsAug 6, 2026
DataApr 2021–Sep 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$2.36B
Trailing 12 months
Net income (TTM)
$26.30M
Trailing 12 months
Revenue growth YoY
+21.4%
Year over year
Operating margin
1.9%
Trailing 12 months
P / E (TTM)
93.8
Trailing earnings · reciprocal yield 1.1%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$412.20M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.6%
Year over year · more shares
Price change (1Y)
-10.4%
Trailing year
Short interest
4.1%
Latest settlement · 3.4 days to cover
AI Brief
Q2 FY26 earnings call · Aug 6, 2026
Q2 FY26
TL;DR. Privia Health delivered strong Q2 2026 results with 12.4% practice collections growth, 29% Adjusted EBITDA growth, and 310 bps of EBITDA margin expansion, and raised full-year 2026 guidance for attributed lives above the prior high end while lifting practice collections/GAAP revenue/care margin/platform contribution/EBITDA to the high or mid-to-high end of prior ranges.
Bullish
- + Adjusted EBITDA grew 29.1% YoY to $37.4M with margin expanding 310 bps
- + Raised full-year 2026 guidance for attributed lives above the high end, practice collections/GAAP revenue to the high end, and care margin/platform contribution/Adjusted EBITDA to the mid-to-high end of prior ranges
- + H1 2026 practice collections grew 13.4% to $1.88B with Adjusted EBITDA up 32.6% to $74.1M, supported by $412M cash and no debt
Bearish
- − CMS may delay final MSSP reconciliation results for performance year 2025 until November, creating atypical year-end cash flow dynamics
- − Free cash flow conversion is now constrained by full cash taxpayer status, with only 70-80% of Adjusted EBITDA expected to convert
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Moderate
Market backdrop
VIX 16.3 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−11%
below
Price vs 50-day avg
−14%
below
RSI (14)
28
oversold
MACD trend
Positive
52-week position
8%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−13%
trailing
6-month return
−6%
trailing
YTD return
−13%
this year
Relative strength
−19%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $24 › 200d $23 — 50d above 200d
Institutional flow
Accumulating
+2% holders QoQ · +46 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.14% of float · ▲ +37.9% MoM · 3.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
300 holders — near 3-yr high, broad support
Squeeze score
61
elevated · 0–100
Fundamentals
Revenue growth
+22%
Y/Y
EPS growth
+64%
Y/Y
Free cash flow
$163.3M
Valuation
P/E 93.8
rich
Quant / Vol
risk profile
Volatility
32%
annualized · 1-yr
Max drawdown
−27%
past year
ATR
3.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−11%
Bearish
Price vs 50-day avg
−14%
Bearish
RSI (14)
28
Neutral
MACD trend
Positive
Bullish
52-week position
8%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $24 › 200d $23 — 50d above 200d
Institutional flow
Accumulating
+2% holders QoQ · +46 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.14% of float · ▲ +37.9% MoM · 3.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
300 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $20
Now $21 · 8%
Range high $28
vs 200-day avg -11%
vs 50-day avg -14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PRVA
this stock
Privia Health Group, Inc.
|
$2.64B | -12.9% | +22.3% | 93.8 | 4.1% |
|
VEEV
Veeva Systems Inc
|
$45.40B | +25.1% | +28.1% | 45.9 | 3.6% |
|
PMDIY
Pro Medicus Ltd./ADR
|
$12.25B | -29.4% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$11.56B | +58.0% | +28.2% | 35.4 | 4.5% |
|
TEM
Tempus AI, Inc.
|
$11.14B | +5.5% | +83.4% | — | 16.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PRVA | -2.6% | -13.2% | -6.5% | +0.7% | -13.0% |
| SPY | -0.5% | -1.2% | +12.6% | -0.7% | +11.7% |
| vs SPY | -2.1% | -12.0% | -19.1% | +1.4% | -24.7% |
Key facts
CIK
1759655
CUSIP
74276R102
13F (30d)
233 filings
233 filers
Visit website
Investor relations